COVID-19 Resource Center
COVID-19 Resource Center
Source:

Press Release

Disclosures: Collins and Fauci report no relevant financial disclosures.
July 27, 2020
1 min read
Save

NIH announces start of phase 3 trial for COVID-19 vaccine

Source:

Press Release

Disclosures: Collins and Fauci report no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The NIH announced the start of a phase 3 clinical trial of the first investigational COVID-19 vaccine given to people in the United States.

Anthony S. Fauci

The vaccine, mRNA-1273, will be studied at 89 clinical research sites in the U.S. in a trial that will involve around 30,000 adult COVID-19-negative volunteers.

The vaccine was developed by the NIH and Moderna, Inc. Researchers began studying it in March. Phase 1 results published this month showed that the vaccine induced anti-SARS-CoV-2 immune responses among participant.

“Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it’s the right goal for the American people,” NIH Director Francis S. Collins, MD, PhD, said in a press release. “The launch of this phase 3 trial in record time while maintaining the most stringent safety measures demonstrates American ingenuity at its best and what can be done when stakeholders come together with unassailable objectivity toward a common goal.”

During the trial, study volunteers will receive two injections 28 days apart of either 100 µg of mRNA-1273 or a saline placebo. The researchers’ primary goals are to determine the safety of the vaccine and evaluate if it can prevent symptomatic COVID-19 after two doses, according to the release. Other objectives include determining if it can prevent severe COVID-19 or lab-confirmed SARS-CoV-2 infection with or without symptoms; and if it can prevent COVID-19-related death.

“Although face coverings, physical distancing and proper isolation and quarantine of infected individuals and contacts can help us mitigate SARS-CoV-2 spread, we urgently need a safe and effective preventive vaccine to ultimately control this pandemic,” National Institute of Allergy and Infectious Diseases Director Anthony S. Fauci, MD, said in the release. “Results from early-stage clinical testing indicate the investigational mRNA-1273 vaccine is safe and immunogenic, supporting the initiation of a phase 3 clinical trial. This scientifically rigorous, randomized, placebo-controlled trial is designed to determine if the vaccine can prevent COVID-19 and for how long such protection may last.”

click me